The pharmaceutical sector in India is showing strong domestic growth of 7% to 9%, despite flat global growth in the US and Europe, according to pharma expert Kewal Handa. He sees good opportunities for Indian companies in the US, as a significant number of patents are set to expire in the next five years. Biosimilars and the application of artificial intelligence in R&D are expected to be major growth areas, and Handa predicts double-digit growth next year.

Related Keywords

India , Kewal Handa , Union Bank , Might Also Like , Pharma Growth , Pharma , Biosimilar , Double Digit Growth , Pharma Sector , Expert View , Stock Market , Et Now ,